Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cellular immunotherapy and cancer.

Edmund K Waller1

  • 1Bone Marrow & Stem Cell Transplant Center, Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA 30322, USA.

Seminars in Oncology
|May 5, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hypoxia-driven T cell-macrophage-stromal cross-talk sustains fibrosis in preclinical models of cutaneous chronic graft-versus-host disease.

Science translational medicine·2026
Same author

T cell-macrophage crosstalk in GVHD and cancer immunotherapy.

Cell investigation·2026
Same author

Vancomycin-Tacrolimus Combination-Related Acute Kidney Injury Risk in Posthematopoietic Stem Cell Transplant Patients.

Transplantation and cellular therapy·2026
Same author

Safety and efficacy of allogeneic CD19-directed CAR-T therapy CTX110 in relapsed/refractory B-cell non-Hodgkin lymphoma.

Blood advances·2026
Same author

Transportability to the European Population of Efficacy of Belumosudil as Compared With Physician's Choice of Best Available Therapy for the Treatment of Chronic Graft Versus Host Disease.

Transplantation and cellular therapy·2026
Same author

Dysbiosis and gastrointestinal GVHD: to treat or not to treat.

Blood·2026
Same journal

A systematic scoping review of cancer-related anemia treatment: Comparative trial outcomes, current guidelines, and future perspectives.

Seminars in oncology·2026
Same journal

Steroid-induced tumor lysis syndrome in solid tumors: A case report and review of the literature.

Seminars in oncology·2026
Same journal

PSMA PET/CT staging in intermediate-risk prostate cancer: Toward risk-adapted implementation.

Seminars in oncology·2026
Same journal

Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms.

Seminars in oncology·2026
Same journal

Post-translational regulation of steroidogenesis and its clinical relevance in hormone responsive cancers.

Seminars in oncology·2026
Same journal

Physics-informed machine learning for tumor microenvironment-responsive nanomedicine: Recent updates.

Seminars in oncology·2026
See all related articles

Cellular immune responses, including T cells and natural killer (NK) cells, show anticancer effects. Enhancing these cellular responses, particularly through dendritic cells and NK cells, holds promise for future cancer therapies.

Area of Science:

  • Immunology
  • Oncology
  • Transplantation

Background:

  • Cellular immune responses, mediated by T cells and natural killer (NK) cells, demonstrate anticancer potential.
  • Two key mechanisms include antigen-specific T cell immunity and antigen-nonspecific NK cell activity.
  • Allogeneic transplants leverage these cellular responses, with HLA matching influencing T cell or NK cell dominance.

Purpose of the Study:

  • To review the roles of T cells and NK cells in cellular anticancer immunity.
  • To discuss the implications of HLA matching in allogeneic transplantation for graft-versus-tumor effects.
  • To explore future strategies for enhancing cellular immune responses against cancer.

Main Methods:

  • Review of recent data on cellular immune responses in cancer.

Related Experiment Videos

  • Analysis of T cell and NK cell mechanisms in graft-versus-tumor effects.
  • Examination of the role of human leukocyte antigen (HLA) in immune recognition and transplant outcomes.

    • Main Results:

    • Antigen-specific T cells and antigen-nonspecific NK cells are crucial for anticancer effects.
    • HLA-mismatched transplants can enhance NK cell activity, while HLA-matched transplants rely on T cells.
    • Expansion of NK cells in HLA-mismatched haplo-identical transplants shows antileukemia effects but is limited by T cell recovery.

    Conclusions:

    • Future cancer immunotherapy may involve activating T cells via dendritic cells or utilizing NK cells for tumors with reduced HLA class I expression.
    • Optimizing cellular immune responses, including T cells and NK cells, is key to improving cancer treatment outcomes.
    • Understanding HLA interactions is critical for harnessing the full potential of cellular immunotherapies in transplantation and beyond.